Literature DB >> 2770531

Hexapropymate self-poisoning causes severe and long-lasting clinical symptoms.

L L Gustafsson1, A Berg, A Magnusson, H O Malmlund, B M Sandell, R Stig.   

Abstract

Cases of hexapropymate poisoning requiring intensive care in an urban region of Sweden (420,000 inhabitants) were collected over 2.5 years (1985 to 1987). Only patients with serum hexapropymate concentrations above 5.5 mg/L (30 mumol/L) and with a negative history for intake of tricyclic antidepressants, phenothiazines, barbiturates, antihistaminic drugs and opiates were included. Clinical data about 8 intoxication events in 6 patients were evaluated retrospectively. Initial symptoms included coma, hypotension, hypothermia, and hypoventilation. Maximum coma depth (Glasgow coma score) was 3 to 5 in 5 out of 8 events. On 7 occasions assisted ventilation was required (for 12 hours or more in 5 events). There was no relationship between serum concentrations of hexapropymate and severity of clinical symptoms. All patients survived. Detailed analysis of the drug elimination in one patient showed a terminal elimination half-life of 21 hours, which is longer than previously reported (5 hours). The indications for use of this hypnotic drug may vary between doctors since an 8-fold variation was seen in drug prescription between Swedish counties in 1987. Poisoning with hexapropymate is a serious condition which may require symptomatic treatment in the intensive care unit. The clinical picture is similar to that seen in patients with burbiturate intoxication. There is no role for active forced elimination of the drug. It is questionable whether the clinical value of the drug is outweighted by its toxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2770531     DOI: 10.1007/BF03259914

Source DB:  PubMed          Journal:  Med Toxicol Adverse Drug Exp        ISSN: 0113-5244


  14 in total

1.  Determination of 1,4-benzodiazepines and -diazepin-2-ones in blood by electron-capture gas-liquid chromatography.

Authors:  J A de Silva; I Bekersky; C V Puglisi; M A Brooks; R E Weinfeld
Journal:  Anal Chem       Date:  1976-01       Impact factor: 6.986

2.  Plasma kinetics of methaqualone in man after single oral doses.

Authors:  G Alván; J E Lindgren; C Bogentoft; O Ericsson
Journal:  Eur J Clin Pharmacol       Date:  1973-10       Impact factor: 2.953

3.  [5 cases of suspected hexapropymate poisoning].

Authors:  A Noirfalise
Journal:  Eur J Toxicol       Date:  1971 Jan-Feb

4.  [A rapid and simple method for the qualitative and quantitative determination of hexapropymate in biological fluids and organs (author's transl)].

Authors:  A Hassoun; R van Binst; M Vandendriessche
Journal:  Toxicol Eur Res       Date:  1978-05

5.  Overdosage of antidepressants: clinical and pharmacokinetic aspects.

Authors:  O L Pedersen; L F Gram; C B Kristensen; M Møller; P Thayssen; M Bjerre; P Kragh-SøRensen; N A Klitgaard; E Sindrup; P Hole; M Brinklø
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Clinical aspects of drug intoxication: barbiturates and a potpourri of other sedatives, hypnotics, and tranquilizers.

Authors:  N E Gary; O Tresznewsky
Journal:  Heart Lung       Date:  1983-03       Impact factor: 2.210

7.  The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden.

Authors:  U Bergman; P Elmes; M Halse; T Halvorsen; H Hood; P K Lunde; F Sjöqvist; O L Wade; B Westerholm
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

8.  Rapid determination of diazepam and nordiazepam in plasma by electron capture gas--liquid chromatography. Application in clinical pharmacokinetic studies.

Authors:  R E Weinfeld; H N Posmanter; K C Khoo; C V Puglisi
Journal:  J Chromatogr       Date:  1977-11-01

9.  The effect of flumazenil (Ro 15-1788) in the management of self-induced benzodiazepine poisoning. A double-blind controlled study.

Authors:  J Höjer; S Baehrendtz
Journal:  Acta Med Scand       Date:  1988

10.  Salicylate clearance, the resultant of protein binding and metabolism.

Authors:  D E Furst; T N Tozer; K L Melmon
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.